Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $823000.0.

  • Compass Therapeutics' Gains from Sales and Divestitures rose 26577.78% to $823000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $823000.0, marking a year-over-year increase of 26577.78%. This contributed to the annual value of $525000.0 for FY2024, which is 7500.0% up from last year.
  • Compass Therapeutics' Gains from Sales and Divestitures amounted to $823000.0 in Q3 2025, which was up 26577.78% from $823000.0 recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Gains from Sales and Divestitures registered a high of $823000.0 during Q1 2025, and its lowest value of $122000.0 during Q2 2023.
  • For the 3-year period, Compass Therapeutics' Gains from Sales and Divestitures averaged around $425300.0, with its median value being $262500.0 (2023).
  • As far as peak fluctuations go, Compass Therapeutics' Gains from Sales and Divestitures skyrocketed by 3888.89% in 2024, and later surged by 26577.78% in 2025.
  • Quarter analysis of 3 years shows Compass Therapeutics' Gains from Sales and Divestitures stood at $300000.0 in 2023, then soared by 75.0% to $525000.0 in 2024, then skyrocketed by 56.76% to $823000.0 in 2025.
  • Its Gains from Sales and Divestitures was $823000.0 in Q3 2025, compared to $823000.0 in Q2 2025 and $823000.0 in Q1 2025.